In 94 malignant mesothelioma patients treated with platinum-based chemotherapy, Patients with homozygous GSTM1 gene deletion have a significantly decreased risk of grade 2-4 leukopenia compared with those of at least one functional allele (OR = 0.43; 95% CI: 0.18–0.99; p = 0.048) (Erčulj et al., 2012). Here, GSTM1 is linked to malignant mesothelioma.